C pyruvate in mitochondria isolated from WT, mpc1D, mpc2D, mpc3D, and mpc2Dmpc3D cells grown in lactate medium (Fig. 3A) . The specificity of uptake was assessed by the use of UK5099, an inhibitor of the mitochondrial pyruvate carrier (14) . Uptake of pyruvate in WT mitochondria was sensitive to the proton ionophore carbonyl cyanide m-chloro phenyl hydrazone (CCCP) (Fig. 3B) . Mitochondria from mpc1D and mpc2Dmpc3D cells showed decreased pyruvate uptake (Fig. 3, A and B) , despite a normal mitochondrial membrane potential ( fig. S5) . Surprisingly, deletion of MPC3 alone impaired pyruvate uptake in mitochondria, whereas mitochondria from the mpc2D mutant transported pyruvate normally. Because this result did not correlate with the phenotypes of mpc2D and mpc3D single mutants grown in SD, we investigated the expression of Mpc2 and Mpc3 in SD and lactate media. In SD, yeast expressed mainly Mpc2, whereas in lactate medium, they mainly expressed Mpc3 (Fig. 3C ). This expression pattern could be explained, at least in part, by the presence of binding sites for Gcn4 (a transcription factor activated by amino acid starvation) upstream of MPC2 (15) . This raises the possibility that under certain growth conditions, these two proteins might have specific, nonredundant functions.
We next assessed whether mouse MPC1 (mMPC1) and MPC2 (mMPC2) could restore growth of yeast cells lacking a functional pyruvate transporter (Fig. 4, A and B) . mMPC1 alone restored growth of mpc1D cells, but mMPC2 failed to restore growth of the double-deletion strain of its orthologous genes MPC2 and MPC3. However, growth of the triple-deletion strain mpc1Dmpc2Dmpc3D or of mpc2Dmpc3D cells was restored by coexpression of both mMPC1 and mMPC2 (Fig. 4A) . Thus, mMPC1 and mMPC2 together functionally complement the absence of pyruvate transport. We next expressed mMPC1 and mMPC2, alone and in combination, in the bacterium Lactococcus lactis (Fig. 4C) , which has been successfully used to express and characterize mitochondrial transporters (16) . No pyruvate uptake was observed in bacteria expressing either protein alone compared with the empty vector control. However, a fourfold increase in pyruvate uptake was detected when mMPC1 and mMPC2 were coexpressed (Fig. 4 , D and E). This uptake was sensitive to the mitochondrial pyruvate carrier inhibitor UK5099 and to 2-deoxyglucose, which collapses the proton electrochemical gradient (Fig. 4E) (17) . Moreover, artificially increasing the membrane potential by lowering the pH in the import buffer from 7.2 to 6.2 significantly increased pyruvate uptake (two-tailed t test, P < 0.05) (Fig. 4E) . Thus, coexpression of mMPC1 and mMPC2 in bacteria is sufficient to allow import of pyruvate with similar properties to the mitochondrial pyruvate carrier (3 P yruvate occupies a pivotal node in the regulation of carbon metabolism as it is the end product of glycolysis and a major substrate for the tricarboxylic acid (TCA) cycle in mitochondria. Pyruvate lies at the intersection of these catabolic pathways with anabolic pathways for lipid synthesis, amino acid biosynthesis, and gluconeogenesis. As a result, the failure to correctly partition carbon between these fates lies at the heart of the altered metabolism evident in diabetes, obesity, and cancer (1, 2). Owing to the fundamental importance of pyruvate, the mitochondrial pyruvate carrier (MPC) has been studied extensively (3, 4) . This included the discovery that a-cyanocinnamate analogs, such as UK-5099, act as specific and potent inhibitors of carrier activity (5) . In spite of this characterization, however, the gene or genes that encode the mitochondrial pyruvate carrier remain unknown (6, 7).
As part of an ongoing effort to characterize mitochondrial proteins that are conserved through evolution, we initiated studies of the MPC protein family (originally designated BRP44 and BRP44L in humans) (8) . This family contains three members in Saccharomyces cerevisiae, encoded by YGL080W, YHR162W, and YGR243W, hereafter referred to as MPC1, MPC2, and MPC3, respectively. Mpc2 and Mpc3 are 79% identical in amino acid sequence and appear to be the product of a recent gene duplication event. Mpc1, Mpc2, and Mpc3 colocalize with mitochondria ( Fig. 1A  and fig. S2A ), consistent with published mitochondrial proteomic studies (9, 10) . The mitochondrial localization of Mpc1 and Mpc2 was confirmed by biochemical fractionation (Fig. 1B) . Mpc1, Mpc2, and Mpc3 were enriched in mitochondrial membranes ( fig. S2B) , consistent with the presence of predicted transmembrane domains in their sequences ( fig. S1 ). Mpc1 and Mpc2 were resistant to protease treatment unless the mitochondrial outer membrane was ruptured (Fig. 1B  and fig. S2C ), implying that they are embedded in the mitochondrial inner membrane. Chromatographic purification of tagged variants of Mpc1 and Mpc2, followed by mass spectrometry, revealed that Mpc2 and Mpc3 were among the major interacting proteins of Mpc1, and Mpc1 and Mpc3 were among the major interacting proteins of Mpc2 (table S1) . Consistent with this, immunoprecipitation of tagged Mpc1 copurified Mpc2 and vice versa ( S2D ). Loss of Mpc2 prevented Mpc1 from migrating in this complex, whereas an mpc1D strain showed elevated Mpc2 complex formation ( fig. S2E ). We conclude that Mpc1 and Mpc2 form a multimeric complex embedded in the mitochondrial inner membrane, with Mpc2 likely being the major structural subunit.
Mutant yeast strains were subjected to a variety of growth conditions. The mpc1D and mpc2D cells displayed mild growth defects on nonfermentable carbon sources like glycerol, with greater effects on glucose medium ( fig. S3 ) and a strong growth defect in the absence of leucine (Fig. 1D ). In contrast, mpc3D mutant displayed no apparent growth phenotypes. Yeast, Drosophila, or human MPC1 orthologs, but not human MPC2, could rescue the mpc1D growth phenotype ( Fig. 1E) , indicating that Mpc1 function is conserved through evolution.
To analyze the physiological function of MPCs in a multicellular animal, we extended our studies to the Drosophila ortholog of MPC1 (dMPC1; encoded by CG14290), which also localized to mitochondria ( fig. S4 ). Analogous to yeast mpc1D mutants, dMPC1 mutants (fig. S5) were viable on standard food, but sensitive to a carbohydrate-only diet, with rapid lethality after transfer to a sucrose medium (Fig. 2A) . Whereas the amount of adenosine 5′-triphosphate (ATP) was reduced in dMPC1 mutants (Fig. 2C) , along with triacylglycerol (TAG) and protein ( fig. S6 , B and C), the amounts of carbohydrates were elevated, including the circulating sugar trehalose (Fig. 2D), glucose (Fig. 2E) , fructose, and glycogen ( fig. S6, A and D) . These results suggest that dMPC1 mutants are defective in carbohydrate metabolism and may consume stored fat and protein for energy. Consistent with this, the lethality of dMPC1 mutants on the sugar diet was rescued by expression of the wild-type gene in tissues that depend heavily on glucose metabolism: the fat body, muscle, and neurons (Fig. 2B) .
Metabolomic analyses revealed that the concentration of pyruvate was highly elevated, whereas TCA cycle intermediates were significantly depleted in dMPC1 mutants on the sugar diet (Fig. 2F) . Similarly, the amounts of glycine and serine, which can interconvert with glycolytic intermediates, were elevated in the mutants on the sugar diet ( fig. S6E ), whereas glutamate, aspartate, and proline, which can interconvert with TCA cycle intermediates, were depleted under these conditions ( fig. S6F ). Consistent with this, metabolomic analysis of mpc1D and mpc2D yeast mutants revealed elevated pyruvate concentrations (Fig. 3A) , depletion of malate ( fig. S7 ), depleted acetyl-coenzyme A (CoA), and elevated CoA concentrations (Fig. 3B) . Taken together, these results suggest that MPC1 mutants are unable to efficiently convert cytosolic pyruvate to mitochondrial acetyl-CoA to drive the TCA cycle and ATP production. These phenotypes could arise from either a defect in mitochondrial pyruvate uptake or the conversion of mitochondrial pyruvate into acetyl-CoA by the pyruvate dehydrogenase (PDH) complex. Yeast lacking Mpc1, however, had nearly wild-type PDH activity, unlike the strong decrease seen in pda1D mutants (Fig. 3C) , which lack PDH function (11) . A decrease in PDH activity also does not explain the growth defect of mpc1D mutants, which is more severe than that of the pda1D mutant ( fig. S8 ). However, combining the mpc1D allele with a deletion for mae1, which encodes a malic enzyme that converts malate to pyruvate in the mitochondrial matrix (12) , revealed a profound growth defect on glucose medium that was completely rescued by plasmid expression of either MAE1 or MPC1 (Fig. 3D) . Notably, mitochondria from the mpc1D mutant displayed almost no uptake of 14 C-pyruvate, which could be fully rescued by plasmid expression of wild-type MPC1 (Fig. 3E) . Moreover, Mpc1 appears to be a key target for UK-5099, which is an inhibitor of the mitochondrial pyruvate carrier (5). The mae1D mpc1D double mutant displayed reduced growth on glucose medium lacking leucine, and this phenotype could be effectively rescued by transgenic expression of wild-type MPC1 in the absence, but not the presence, of UK-5099 (Fig. 3F) . By screening for MPC1 mutants that could grow in the presence of UK-5099, we recovered an Asp 118 →Gly (D118G) substitution in Mpc1 that conferred UK-5099 resistance (Fig.  3F) . Moreover, whereas 14 C-pyruvate uptake into mitochondria expressing wild-type MPC1 was almost completely inhibited by UK-5099, efficient pyruvate uptake that is resistant to UK-5099 was recovered upon expression of MPC1-D118G (Fig.  3G) . We conclude that Mpc1 is a key component of the mitochondrial pyruvate carrier that corresponds to the activity studied for decades by Halestrap and others (5, 13) .
Depletion of MPC1 in mouse embryonic fibroblasts ( fig. S9A ) caused a modest decrease in pyruvatedriven oxygen consumption under basal conditions, and a stronger reduction in the presence of carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), which stimulates maximal respiration (Fig. 4A) . Similar results were also seen upon silencing MPC2 (Fig. 4B and fig. S9A ). This suppression of pyruvate oxidation, which occurred without affecting components of the oxidative phosphorylation machinery ( fig. S9 , B and C), suggests that mammalian Mpc1 and Mpc2 mediate mitochondrial pyruvate uptake in a manner similar to that seen in yeast and Drosophila.
We have previously described a FrenchAlgerian family with two offspring that exhibited a devastating defect in mitochondrial pyruvate oxidation (14) (Fig. 4C, family 1) . We subsequently discovered two additional families, each with one affected child who displayed a similar, but less severe, phenotype (Fig. 4C, families 2 and 3) . Linkage analysis and homozygosity mapping allowed us to focus on one candidate region on chromosome 6 (163,607,637 to 166,842,083, GRCh37/hg19). This interval contained 10 potential candidate genes: PACRG, QKI, C6orf118, PDE10A, SDIM1, T, PRR18, SFT2D1, RPS6KA2, and BRP44L, which is the human MPC1. DNA sequencing of the exons and intron/exon boundaries of the MPC1 gene in fibroblasts from the affected patients in families 2 and 3 revealed the same molecular lesion, c.236T→A, causing a predicted p.Leu 79 →His (L79H) alteration (Fig. 4D) . Analysis of DNA from family 1 revealed a distinct sequence change, c.289C→T, which resulted in a predicted p.Arg 97 →Trp (R97W) mutation (Fig. 4D) . Both of the affected residues are conserved through evolution between MPC1 orthologs, and Arg 97 is conserved among both MPC1 and MPC2 orthologs ( fig. S1 ).
Cells from the affected individuals in families 1 and 2 exhibited impaired basal and FCCPstimulated pyruvate oxidation (Fig. 4E) , whereas glutamine-driven oxygen consumption was normal or elevated, demonstrating that they have not acquired a generalized impairment of mitochondrial respiration (Fig. 4E) . As expected, expression of wild-type human MPC1 in the cells from family 2 (Fig. 4F) or family 1 (Fig. 4G ) either completely or partially rescued the defect in FCCP-induced pyruvate oxidation. Moreover, expression of the MPC1-Leu79His allele was less effective at suppressing the yeast mpc1D growth defect relative to wild-type human MPC1 ( + or dMPC -flies after 2 days on the indicated diet as measured by gas chromatography-mass spectrometry. *P < 0.05, **P < 0.01, and ***P < 0.001 (Student's t test) . Data are shown as mean T SEM. C-pyruvate into mitochondria isolated from the mpc1D strain containing the indicated plasmid in the presence or absence of UK-5099. ***P < 0.001, **P < 0.01, *P < 0.05; NS, not significant (Student's t test). Data are shown as mean T SEM.
www.sciencemag.org SCIENCE VOL 337 6 JULY 2012 99 REPORTS on July 7, 2012 www.sciencemag.org essentially inactive (Fig. 4H) , suggesting that MPC1 function is evolutionarily conserved from yeast to humans.
The data presented here demonstrate that the Mpc1-Mpc2 complex is an essential component of the mitochondrial pyruvate carrier in yeast, flies, and mammals. This is consistent with experiments performed in rat liver, heart, and castor beans, which implicated proteins of 12 to 15 kD in mitochondrial pyruvate uptake (15)-similar to the molecular masses of Mpc1 (15 kD), Mpc2 (14 kD), and Mpc3 (16 kD). Although these individual sizes are relatively small, Mpc1 and Mpc2 form a complex of~150 kD, suggesting that an oligomeric structure mediates pyruvate transport. The demonstration that Mpc1 and Mpc2 are sufficient to promote pyruvate uptake in a heterologous system provides further evidence that they constitute an essential pyruvate transporter (16) . Finally, the degree to which carbohydrates are imported into mitochondria and converted into acetyl-CoA is a critical step in normal glucose oxidation as well as the onset of diabetes, obesity, and cancer. Thus, like PDH, which is controlled by allostery and posttranslational modification (17) , the mitochondrial import of pyruvate is likely to be precisely regulated (18, 19) . The identification of Mpc1 and Mpc2 as critical for mitochondrial pyruvate transport provides a new framework for understanding this level of metabolic control, as well as new directions for potential therapeutic intervention.
